Skin Aging Clinical Trial
Official title:
A Prospective, Multicentric, Open-labelled, Interventional Study to Assess Skin Beautification by Treating Fine Lines in the Neck, Perioral and Smiling Lines Areas With TEOSYAL RHA® 1
Verified date | May 2022 |
Source | Teoxane SA |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Prospective, low-interventional, multicentric, open-labelled study to assess the performance and safety of skin beautification treatment by TEOSYAL RHA® 1 for fine lines in the neck, perioral region, and smiling lines including an exploratory arm with TEOSYAL® PureSense Redensity 1 to assess skin redensification. Treatment phase - skin beautification: At Visit 1 (Baseline), subjects will be injected with TEOSYAL RHA® 1 in the fine lines (Neck lines and Perioral and/or Smiling lines) depending on wrinkle severity assessed by the Principal Investigator (PI) at baseline using a specific grading scale for each indication. The subject will be included in the study if he has been graded 2 or 3 on the Neck Lines Descriptive Scale (NLDS) at baseline. Then: 1. The subject will be included in the perioral rhytids cohort if he has been graded 2 or 3 on the Perioral Rhytids Severity Rating Scale (PR-SRS) at baseline. 2. The subject will be included in the smiling lines cohort if he has been graded 3 or 4 on the Smiling Lines Descriptive Scale (SLDS) at baseline. Each indication represent one cohort and all subjects will be included in the neck lines cohort. Thus, Subject participating to the study may be treated for: - Neck Lines and perioral Lines (2 cohorts) - Neck Lines and Smiling Lines (2 cohorts) - Neck Lines, Perioral Lines and Smiling Lines (3 cohorts) An optional touch-up will be performed at Visit 2 (Month 1 +/- 1 week) if deemed necessary to achieve an optimal correction. Exploratory phase - skin redensification: After treatment with TEOSYAL RHA® 1, subjects will be randomized to the second phase of the study (starting at month 2 +/- 1 week): 5/6 of the subjects will enter the exploratory part of the study during which TEOSYAL® PureSense Redensity 1 (RHA1+R1 treated Group) will be assessed for skin redensification. The rest of the subjects will not receive any additional treatment for the rest of the study (RHA1 only treated group/around 11 subjects). Note: the number of sessions treated with Redensity 1 might be adapted depending on subject treatment needs in order to achieve optimal results. This will be at PI discretion. Subjects in the RHA+R1 treated Group will be also randomized into 2 subgroups of 28 subjects as described below: - Sub-Group A: injection with a needle for all indications - Sub-Group B: injection with a cannula for neck lines and smiling lines indications* *The perioral indication will be treated with a needle for this group. The principal investigator (PI) will perform the study injections. He will evaluate subject aesthetic improvement using grading scales and skin quality measurements at each study visits and assess safety and tolerability of the devices during the study. Adverse events will be monitored by the Clinical Research Associate (CRA) throughout the study. Additionally, a Blinded Evaluator will also evaluate subject aesthetic improvement using grading scales for each follow-up visits based on photographs.
Status | Active, not recruiting |
Enrollment | 67 |
Est. completion date | May 31, 2022 |
Est. primary completion date | December 13, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 35 Years to 70 Years |
Eligibility | Inclusion Criteria (General): 1. Healthy adults, 35 to 70 years old seeking an improvement of their aesthetic appearance and beautification of their skin in 3 areas: perioral lines, smiling lines and neck lines. 2. Subjects having given their informed consent. 3. Subjects having wrinkle severity ranked as mild to moderate neck lines (grade 2 or grade 3 on the NLDS) Inclusion Criteria (Cohort) 4. Healthy adult having wrinkle severity in at least one of the two indications (50% for each of the following cohort): i. Moderate to severe perioral rhytids (grade 2 or grade 3 on the PR-SRS) ii. Moderate to severe smiling lines (grade 3 or grade 4 on the SLDS) Exclusion Criteria: 1. Minor subjects 2. Subjects who already had fillers and/or other skin quality treatment(s) in the 6 months preceding the study. 3. Subjects undergoing or planning to undergo peeling treatment or laser/ultrasound-based treatment during the study or having had one of these treatments in the 6 months preceding the study. 4. Subjects showing cutaneous disorders, inflammation or infection (acne, herpes, scars…) at the treatment site or near to this site. 5. Subjects having a known hypersensibility to lidocaine and/or amide local anesthetic agents or hyaluronic acid, or with history of severe allergy or anaphylactic shock. 6. Subjects with autoimmune or cardiac diseases and/or undergoing treatment for heart diseases (beta blockers). 7. Subjects with hepatocellular insufficiency and/or undergoing treatment for liver disease. 8. Subjects suffering from epilepsy or porphyria. 9. Subjects with severe, ongoing and/or uncontrolled disease that may pose a health risk to the subject during the study and/or may have an impact on the study assessments. 10. Subjects receiving or planning to receive high dose Vitamin E, aspirin, anti-inflammatories, or anti-coagulant during the week preceding each injection. 11. Subjects receiving any long-term medical treatment or any treatment that, in the opinion of the clinical investigator, may interfere with test results or put the subject at undue risk. 12. Subjects under guardianship/tutorship. 13. Pregnant women or breastfeeding mother. 14. Subjects participating to another research on human beings or being in an exclusion period for a previous study. |
Country | Name | City | State |
---|---|---|---|
Spain | Site 4 | Alicante | |
Spain | Site 3 | Barcelona | |
Spain | Site 1 | Bilbao | |
Spain | Site 2 | Madrid |
Lead Sponsor | Collaborator |
---|---|
Teoxane SA |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of subjects improved or much improved on the Global Aesthetic Improvement Scale (GAIS) according to both the Principal Investigator (PI) and the subject. | The Global Aesthetic Improvement Scale (GAIS) is a subjective 5-grade scale comprised of "much improved, improved, no change, worse, and much worse". | Visit 3 (Month 2) | |
Secondary | Proportion of subjects improved or much improved on the Global Aesthetic Improvement Scale (GAIS) according to the Principal Investigator (PI) | The Global Aesthetic Improvement Scale (GAIS) is a subjective 5-grade scale comprised of "much improved, improved, no change, worse, and much worse". | Visit 2 (Month 1), Visit 3 (Month 2), Visit (Month 3), Visit 5 (Month 4), Visit 6 (Month 5) | |
Secondary | Proportion of subjects improved or much improved on the Global Aesthetic Improvement Scale (GAIS) according to the subject | The Global Aesthetic Improvement Scale (GAIS) is a subjective 5-grade scale comprised of "much improved, improved, no change, worse, and much worse". | Visit 2 (Month 1), Visit 3 (Month 2), Visit (Month 3), Visit 5 (Month 4), Visit 6 (Month 5) | |
Secondary | Proportion of subjects improved or much improved on the Global Aesthetic Improvement Scale (GAIS) according to the Blinded Evaluator (BE) | The Global Aesthetic Improvement Scale (GAIS) is a subjective 5-grade scale comprised of "much improved, improved, no change, worse, and much worse". | Visit 2 (Month 1), Visit 3 (Month 2), Visit (Month 3), Visit 5 (Month 4), Visit 6 (Month 5) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04276753 -
A Randomized, Double-blinded, Placebo Controlled, Monocentric Study to Evaluate the Anti-ageing and Skin Brightening Benefit of the Test Product in Healthy Female Subjects
|
N/A | |
Completed |
NCT06125912 -
A Comparative Split-Face Study of the Effects of a Retinol Alternative Cream on Improving Facial Skin Aging
|
N/A | |
Completed |
NCT02580370 -
Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines
|
Phase 3 | |
Recruiting |
NCT01583478 -
Comparison of Escalating Doses of IncobotulinumtoxinA (Xeomin®) in the Treatment of Glabellar Rhytids
|
Phase 4 | |
Completed |
NCT02003833 -
Poly-L-lactic Acid for Skin Quality
|
Phase 4 | |
Completed |
NCT01447342 -
A Study to Evaluate the Safety and Effectiveness of the Cryo-Touch II Device for the Treatment of Forehead and/or Glabellar Lines
|
Phase 2/Phase 3 | |
Completed |
NCT00986570 -
Clinical Trial to Assess Efficacy, Safety and Tolerability of Botulinum Toxin A (Xeomin®) in Treatment of Expression Wrinkles in the Upper Third of the Face
|
Phase 3 | |
Completed |
NCT00974480 -
Comparison of Redermic, Rejuva-A and Combination of Both Redermic and Rejuva-A in Subjects With Signs of Aging
|
N/A | |
Completed |
NCT00272610 -
Topical Vitamin A Versus Vehicle Cream in the Treatment of Aged Skin
|
Phase 2 | |
Recruiting |
NCT03730649 -
Effect of Topical Sulforaphane on Skin Aging and With Ultraviolet and Visible Light Exposure
|
Early Phase 1 | |
Completed |
NCT03312543 -
Evaluation of the Efficacy and Tolerance of a Light Therapy Mask on Mild to Moderate Brown Spots and Moderate to Severe Facial Wrinkles
|
N/A | |
Completed |
NCT03677258 -
Effectiveness and Safety of Collagen Complex COLLOST in Anti-age Therapy
|
N/A | |
Withdrawn |
NCT05854628 -
The Role of Red Flavonoid in Photoaging
|
N/A | |
Completed |
NCT01981980 -
Comparison of the Effects of Carboxytherapy and Radiofrequency on Skin Rejuvenation
|
N/A | |
Not yet recruiting |
NCT00767156 -
Effects of Oral and Topical Sea Buckthorn Oil Treatments on Skin Aging
|
N/A | |
Recruiting |
NCT05813054 -
Clinical Study to Evaluate the Anti-aging Efficacy of Dermial®
|
N/A | |
Not yet recruiting |
NCT04485091 -
TCA Peel and Photobiomodulation for Hand Rejuvenation
|
Phase 2 | |
Completed |
NCT05457491 -
Novel Antiaging Regenerative Skin Care Regimen Containing Human Platelet Extract (HPE)
|
Phase 1 | |
Completed |
NCT01237977 -
Efficacy and Safety Study of Botulinum Toxin Type A to Treat Glabellar Lines
|
Phase 3 | |
Completed |
NCT01029301 -
Evaluation of Safety and Efficacy of Using EndyMed Pro Skin Treatment System for Skin Wrinkle Treatment on Body Areas
|
N/A |